ImmuneWorks LLC announced today that it has been awarded a $1.5 million grant from the Indiana 21st Century Research and Technology Fund. ImmuneWorks will use these funds to complete preclinical development of its lead product in the treatment of idiopathic pulmonary fibrosis. ImmuneWorks LLC is a biotechnology company developing novel therapeutics and diagnostic tests for patients with autoimmune conditions. It was founded in 2006 by Indiana University School of Medicine researchers Drs. David Wilkes and Michael Klemsz. The company is initially developing treatments for pulmonary diseases such as idiopathic pulmonary fibrosis and prevention of lung transplant rejection.
Wednesday, December 12, 2007
ImmuneWorks LLC Wins $1.5 Million Grant
ImmuneWorks LLC announced today that it has been awarded a $1.5 million grant from the Indiana 21st Century Research and Technology Fund. ImmuneWorks will use these funds to complete preclinical development of its lead product in the treatment of idiopathic pulmonary fibrosis. ImmuneWorks LLC is a biotechnology company developing novel therapeutics and diagnostic tests for patients with autoimmune conditions. It was founded in 2006 by Indiana University School of Medicine researchers Drs. David Wilkes and Michael Klemsz. The company is initially developing treatments for pulmonary diseases such as idiopathic pulmonary fibrosis and prevention of lung transplant rejection.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment